Clinical neuroscience

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Monday, April 1, 2024
Employment, Brain, ALS, Patient, CNS, SVP, Cell biology, Bristol Myers Squibb, University, Initial, Myelocyte, Therapy, Drug development, Alkahest, Yale school, Clinical neuroscience, Compensated emancipation, Pharmaceutical industry

“I am pleased to welcome Jonas to Gain and look forward to his contributions.

Key Points: 
  • “I am pleased to welcome Jonas to Gain and look forward to his contributions.
  • His academic work focused on immuno-neurology, particularly on the effect of systemic inflammation on myeloid cells in the brain.
  • Previously, he served as Chief Medical Officer at Tranquis Therapeutics and Capacity Bio, SVP of Clinical Development at Alkahest, Medical Director at Denali Therapeutics, and Director of Neuroscience Discovery Medicine at UCB Pharma.
  • “Looking at the extensive data package that the Gain team has generated during preclinical development, Gain’s lead drug candidate GT-02287 has a first and best-in-class profile.

IntelGenx Announces Research Collaboration with Renowned Neurologist to Evaluate Montelukast VersaFilm® for the Treatment of Parkinson’s Disease

Retrieved on: 
Thursday, February 9, 2023
Disease, Movement disorders, Neurodegeneration, Parkinson, Cysteinyl leukotriene receptor 1, Karolinska Institute, Immunomodulation, Trial of the century, Principal, Clinical neuroscience, Per Svenningsson, TSX, Swedish Research Council, Government budget balance, Parkinson's disease, Intellectual property, Lewy body, Clinical trial, Alzheimer's disease, Leukotriene, SCI, Research, Doctor of Philosophy, Pharmaceutical industry, MD, PD, Study

$2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.

Key Points: 
  • $2 million USD) awarded by the Swedish Research Council, Sweden’s largest governmental research funding body.
  • IntelGenx will supply Dr. Svenningsson with both active and placebo films to be used in the 18-month treatment regimen for study participants.
  • Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
  • 2 Wallin, J; Svenningsson, P. Potential Effects of Leukotriene Receptor Antagonist Montelukast in Treatment of Neuroinflammation in Parkinson’s Disease.

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Retrieved on: 
Wednesday, January 18, 2023
American Board of Psychiatry and Neurology, Protalix BioTherapeutics, Merck, Pharmacology, Mental health, CNS, American Board of Commissioners for Foreign Missions, Reunion, TSX, Head, Merck & Co., AstraZeneca, Patient, Clinical neuroscience, Neurology, University, Data analysis, Takeda Pharmaceutical Company, Pfizer, GSK, Psychiatry, Psychopharmacology, Pharmaceutical industry, GlaxoSmithKline, Takeda

TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed Robert Alexander, M.D.

Key Points: 
  • TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed Robert Alexander, M.D.
  • as the Company’s Chief Medical Officer, effective immediately.
  • Prior to Takeda, Dr. Alexander served as Chief Medical Officer, BioTherapeutics, at Pfizer, directing clinical pharmacology and statistics groups while simultaneously holding the position of Vice President and Head of the Clinical Neuroscience and Pain Research Unit at the company.
  • Second, the Company’s strong intellectual property position gives Reunion a significant competitive advantage over others in the space,” added Dr. Alexander.

Applied Pharmaceutical Innovation (API) announces establishment of team with researchers from Nova Scotia Universities for antiviral drug discovery against SARS-CoV-2 and RNA viruses

Retrieved on: 
Thursday, March 31, 2022
Comparison of chemistry and physics, Industry, Virus, Medicine, Dalhousie, Organization, Clinical neuroscience, Therapy, Patent, Microbiology, Mount Saint Vincent University, Orthornavirae, Physics, Research, Chemistry, Environment, Dalhousie University, CEO, RNA, Severe acute respiratory syndrome coronavirus 2, API, Immunology, AB, COVID-19, Student, FDA, Pharmaceutical industry, Medical device, Fine chemical, Tioguanine

The researchers and API plan to use this information to develop novel chemical entities with greater specificity and potency that can be used for improved antiviral drug discovery against SARS-CoV-2 and RNA viruses.

Key Points: 
  • The researchers and API plan to use this information to develop novel chemical entities with greater specificity and potency that can be used for improved antiviral drug discovery against SARS-CoV-2 and RNA viruses.
  • In addition to providing the researchers with access to expertise and infrastructure, the project will involve API employing a team at Dalhousie.
  • This collaboration will also add to the antiviral drug discovery pipeline, strengthening Canada's pandemic preparedness against viruses like COVID-19."
  • Applied Pharmaceutical Innovation (API) is a not-for-profit institute making an impact in the life sciences by bridging the gap between academia and industry.

New Study by Curelator Reveals Surprisingly Variable Relationship between Peak Pain Severity and Stress in Individuals with Chronic Migraine

Retrieved on: 
Wednesday, September 22, 2021
Trigger, Universitat (Barcelona Metro), University of Calgary, 2021 Essex County Council election, Clinical neuroscience, Curel, Patient, Risk, Smartphone, Personal, Alberta Children's Hospital, Hospital, Statistics, Cummings School of Veterinary Medicine, Migraine, Headache, Cumming School of Medicine, Death, University, Disease management, Trafficking in Persons Report, Pain, Disease, History, Divorce, Association mapping, Assistant professor, Aroma compound, Aquaculture, Poultry, Medicine

CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Curelator Inc. today announced new data with what is the first study to prospectively examine daily peak pain severity patterns and the day-to-day relationship between peak severity and perceived stress, in individuals with chronic migraine.

Key Points: 
  • - The study concluded that, on average, peak pain severity was higher on days in which the individual perceived higher stress levels.
  • CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Curelator Inc. today announced new data with what is the first study to prospectively examine daily peak pain severity patterns and the day-to-day relationship between peak severity and perceived stress, in individuals with chronic migraine.
  • Some individuals showed no relationship between stress and peak pain severity, or even presented lower peak severity on days with higher stress.
  • Perceived stress and pain severity in individuals with chronic migraine: a longitudinal cohort study using daily prospective diary data.

New Study by Curelator Reveals Surprisingly Variable Relationship between Peak Pain Severity and Stress in Individuals with Chronic Migraine

Retrieved on: 
Wednesday, September 22, 2021
Trigger, Universitat (Barcelona Metro), University of Calgary, 2021 Essex County Council election, Clinical neuroscience, Curel, Patient, Risk, Smartphone, Personal, Alberta Children's Hospital, Hospital, Statistics, Cummings School of Veterinary Medicine, Migraine, Headache, Cumming School of Medicine, Death, University, Disease management, Trafficking in Persons Report, Pain, Disease, History, Divorce, Association mapping, Assistant professor, Poultry, Medicine

CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Curelator Inc. today announced new data with what is the first study to prospectively examine daily peak pain severity patterns and the day-to-day relationship between peak severity and perceived stress, in individuals with chronic migraine.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 22, 2021 /PRNewswire/ -- Curelator Inc. today announced new data with what is the first study to prospectively examine daily peak pain severity patterns and the day-to-day relationship between peak severity and perceived stress, in individuals with chronic migraine.
  • divorce or death of a family member, may increase the risk of progression to chronic migraine, whilst day to day stress levels may be associated with occurrence and/or the peak pain severity of migraine attacks.
  • Some individuals showed no relationship between stress and peak pain severity, or even presented lower peak severity on days with higher stress.
  • Perceived stress and pain severity in individuals with chronic migraine: a longitudinal cohort study using daily prospective diary data.

2020 Global Central Nervous System Disorders Pipeline Database - ResearchAndMarkets.com

Retrieved on: 
Friday, May 29, 2020
Health, Pharmaceutical, Organ systems, Branches of biology, Nervous system, Central nervous system disease, Nervous system disease, Neurotransmitters, Clinical neuroscience, ICD-10 Chapter VI: Diseases of the nervous system

The "Central Nervous System Disorders Pipeline Database - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Central Nervous System Disorders Pipeline Database - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This database provides the most up-to-date information on key pipeline products in the global Central Nervous System (CNS) disorders drug market.
  • Key indications covered in this database include Multiple Sclerosis, Depression, Alzheimer's disease, Parkinson's disease, ADHD, Schizophrenia, Epilepsy, Migraine, and Huntington's disease.
  • The database provides CNS disorders pipeline products by their dominant drug mechanism class.